Skip to main content

and
  1. No Access

    Article

    Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)

    A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) su...

    C Tarella, M Zanni, M Di Nicola, C Patti, R Calvi, A Pescarollo, V Zoli in Leukemia (2007)